Teva Didn't Infringe OxyContin Patents, NY Judge Rules

Law360, Los Angeles (January 14, 2014, 6:32 PM EST) -- A New York federal judge on Tuesday found that Teva Pharmaceuticals USA Inc. did not infringe any valid Purdue Pharma LP patent when it attempted to sell a generic version of narcotic pain medication OxyContin.

U.S. District Judge Sidney H. Stein concluded that Purdue had failed to prove Teva had infringed U.S. Patent Number 7,776,314 when it sought approval from the U.S. Food and Drug Administration to sell bioequivalents of OxyContin, and that the asserted claims in the remaining four patents-in-suit — U.S. Patent Numbers 7,674,799,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.